ମିଗ୍ଲୁଷ୍ଟାଟ

ମିଗ୍ଲୁଷ୍ଟାଟ
Clinical data
Trade names	Zavesca, Brazaves
Synonyms	OGT 918, 1,5-(butylimino)-1,5-dideoxy-D-glucitol, N-butyl-deoxynojirimycin
AHFS/Drugs.com	monograph
MedlinePlus	a604015
data	EU EMA: yes; US DailyMed: Miglustat;
Pregnancy; category	AU: D ; US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	97%
Protein binding	Nil
Metabolism	Nil
Elimination half-life	6–7 hours
Excretion	Kidney, unchanged
Identifiers
	IUPAC name (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol;
ECHA InfoCard	100.216.074
Chemical and physical data
Formula	C10H21NO4
Molar mass	୨୧୯.୨୮ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O;
	InChI InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 ; Key:UQRORFVVSGFNRO-UTINFBMNSA-N ;
(verify)

ମିଗ୍ଲୁଷ୍ଟାଟ (ଇଂରାଜୀ ଭାଷାରେ Miglustat), ଜାଭେସ୍କା ଏହାର ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଗାଉଚର ରୋଗ ପ୍ରକାର ୧ (GD1) ଏବଂ ନିମାନ-ପିକ ରୋଗ ପ୍ରକାର ଗ (NPC) ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଓଜନ ହ୍ରାସ, କମ୍ପନ, ତରଲ ଝାଡ଼ା, ଅନ୍ତନଳୀସ୍ଥ ବାୟୁ ବୃଦ୍ଧି ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୩] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ପେରିଫେରାଲ୍ ନ୍ୟୁରୋପାଥି ବା ପ୍ରାନ୍ତୀୟ ସ୍ନାୟୁରୋଗ ଏବଂ କମ୍ ରକ୍ତ ପ୍ଲାଟେଲେଟ୍ ହୋଇପାରେ ।^[୫] ଗର୍ଭାବସ୍ଥାରେ ଏହି ଔଷଧ ଯୋଗୁ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୫] ଏହା ଏକ ଗ୍ଲୁକୋସିଲସେରାମାଇଡ୍ ସିନ୍ଥେଜ୍ ଇନହିବିଟର ।^[୫]

୨୦୦୨ ମସିହାରେ ୟୁରୋପ ଏବଂ ୨୦୦୩ରେ ଆମେରିକାରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ମିଗ୍ଲୁଷ୍ଟାଟ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ^[୫] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୬] ଯୁକ୍ତରାଜ୍ୟରେ ୪ ସପ୍ତାହର ଔଷଧ କ୍ରୟ ଖର୍ଚ୍ଚ ୨୦୨୧ ସୁଦ୍ଧା ୩୪୦୦ ପାଉଣ୍ଡ ଥିଲା ।^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୨୩,୦୦୦ ଡଲାର ଅଟେ ।^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Miglustat (Zavesca) Use During Pregnancy". Drugs.com. 4 February 2020. Archived from the original on 28 November 2020. Retrieved 7 August 2020.
↑ "Summary for ARTG Entry:122957 Zavesca miglustat 100 mg capsules blister pack". Therapeutic Goods Administration.{{cite web}}: CS1 maint: url-status (link)
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Zavesca EPAR". European Medicines Agency (EMA). Archived from the original on 5 August 2020. Retrieved 7 August 2020.
↑ "Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 25 February 2021. Retrieved 7 August 2020.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "Miglustat Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 18 November 2021.
↑ ^୬.୦ ^୬.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1117. ISBN 978-0857114105.
↑ "Miglustat Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 18 April 2021. Retrieved 18 November 2021.

[Drugs.com_pregnancy-1] ୧.୦ ^୧.୧ "Miglustat (Zavesca) Use During Pregnancy". Drugs.com. 4 February 2020. Archived from the original on 28 November 2020. Retrieved 7 August 2020.

[2] "Summary for ARTG Entry:122957 Zavesca miglustat 100 mg capsules blister pack". Therapeutic Goods Administration.{{cite web}}: CS1 maint: url-status (link)

[EPAR2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Zavesca EPAR". European Medicines Agency (EMA). Archived from the original on 5 August 2020. Retrieved 7 August 2020.

[4] "Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 25 February 2021. Retrieved 7 August 2020.

[AHFS2021-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "Miglustat Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 18 November 2021.

[BNF81-6] ୬.୦ ^୬.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1117. ISBN 978-0857114105.

[7] "Miglustat Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 18 April 2021. Retrieved 18 November 2021.

[୩]

[୫]

[୧]

[୨]

[୪]

[୬]

[୭]